文献速递淋巴瘤

利妥昔单抗暴露受基线代谢肿瘤体积影响并预测弥漫性大B细胞淋巴瘤患者结局:淋巴瘤研究协会报告

Rituximab exposure is influenced by baseline metabolic tumor volume and predicts outcome of DLBCL patients: a Lymphoma Study Association report.
PubMed 文献 · Blood · 2017-03-01

在108例未经治疗的弥漫性大B细胞淋巴瘤患者中,基线总代谢肿瘤体积(TMTV0)越大,利妥昔单抗暴露越低(R2=0.41,P<.0001)。第1周期AUC≥9400 mg×h/L与更好的代谢反应、更长的无进展生存和总生存相关。根据TMTV0构建的列线图显示,375 mg/m2经典剂量适用于TMTV0<281 cm3的患者。

要点

  • TMTV0越高,利妥昔单抗暴露越低(R2=0.41,P<.0001)。
  • 第1周期AUC≥9400 mg×h/L与更好反应、更长PFS和OS相关。
  • 375 mg/m2经典剂量适用于TMTV0<281 cm3的患者。

核心结论

  • 利妥昔单抗暴露受TMTV0影响,并与弥漫性大B细胞淋巴瘤患者的反应和结局相关。
  • 作者认为应根据TMTV0进行剂量个体化,并应在前瞻性研究中评估。

研究设计与样本

  • 研究纳入108例未经治疗的弥漫性大B细胞淋巴瘤患者,来自2项前瞻性试验。
  • 患者接受每2周一次、共4次375 mg/m2利妥昔单抗输注联合化疗。
  • 采用18F-氟脱氧葡萄糖-正电子发射断层扫描-计算机断层扫描测量TMTV0。
  • 采用二室群体模型描述利妥昔单抗药代动力学并计算暴露量(浓度-时间曲线下面积,AUC)。

主要发现

  • 利妥昔单抗暴露随TMTV0增加而降低(R2=0.41,P<.0001)。
  • 第1周期高AUC(≥9400 mg×h/L)与更好的反应相关(比值比5.56;P=.0006)。
  • 第1周期高AUC(≥9400 mg×h/L)与更长的无进展生存相关(风险比0.38;P=.011)。
  • 第1周期高AUC(≥9400 mg×h/L)与更长的总生存相关(风险比0.17;P=.001)。
  • 根据TMTV0构建了获得最佳AUC所需利妥昔单抗剂量的列线图,375 mg/m2经典剂量适用于TMTV0<281 cm3的患者。

关键数值与推荐

  • 第1周期AUC≥9400 mg×h/L与更好反应相关(比值比5.56;P=.0006)。
  • 第1周期AUC≥9400 mg×h/L与更长无进展生存相关(风险比0.38;P=.011)。
  • 第1周期AUC≥9400 mg×h/L与更长总生存相关(风险比0.17;P=.001)。
  • 375 mg/m2经典剂量适用于TMTV0<281 cm3的患者。

临床怎么用

  • 作者认为应根据TMTV0进行剂量个体化,并应在前瞻性研究中评估。

局限性

  • 作者认为应根据TMTV0进行剂量个体化,并应在前瞻性研究中评估。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

High variability in patient outcome after rituximab-based treatment is partly explained by rituximab concentrations, and pharmacokinetic (PK) variability could be influenced by tumor burden. We aimed at quantifying the influence of baseline total metabolic tumor volume (TMTV0) on rituximab PK and of TMTV0 and rituximab exposure on outcome in patients with diffuse large B-cell lymphoma (DLBCL). TMTV0 was measured by 18F-fluorodeoxyglucose-positron emission tomography-computed tomography in 108 previously untreated DLBCL patients who received four 375 mg/m2 rituximab infusions every 2 weeks in combination with chemotherapy in 2 prospective trials. A 2-compartment population model allowed describing rituximab PK and calculating rituximab exposure (area under the concentration-time curve; AUC). The association of TMTV0 and AUC with metabolic response after 4 cycles, as well as progression-free survival (PFS) and overall survival (OS), was assessed using logistic regression and Cox models, respectively. Cutoff values for patient outcome were determined using receiver operating characteristic curve analysis. Exposure to rituximab decreased as TMTV0 increased (R2 = 0.41, P < .0001). A high AUC in cycle 1 (≥9400 mg × h per liter) was associated with better response (odds ratio, 5.56; P = .0006) and longer PFS (hazard ratio [HR], 0.38; P = .011) and OS (HR, 0.17; P = .001). A nomogram for rituximab dose needed to obtain optimal AUC according to TMTV0 was constructed, and the 375 mg/m2 classical dose would be suitable for patients with TMTV0 <281 cm3 In summary, rituximab exposure is influenced by TMTV0 and correlates with response and outcome of DLBCL patients. Dose individualization according to TMTV0 should be evaluated in prospective studies. These studies were registered at www.clinicaltrials.gov as #NCT00498043 and #NCT00841945.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Tout M, Casasnovas O, Meignan M, et al. Rituximab exposure is influenced by baseline metabolic tumor volume and predicts outcome of DLBCL patients: a Lymphoma Study Association report. Blood. 2017. PMID: 28251914. doi:10.1182/blood-2016-10-744292

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。